| 5-HT | 5-hydroxytryptamine (serotonin) |
| ADRs | adverse drug reactions |
| AMPA | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (glutamate receptors) |
| BDNF | brain derived neurotrophic factor |
| CNS | central nervous system |
| COX-2 | cyclooxygenase 2 |
| GABA | gamma aminobutyric acid |
| HPA | hypothalamic-pituitary-axis |
| SSRIs | selective serotonin reuptake inhibitors |
| Il | interleukin |
| INF-γ | interferon-γ |
| iNOS | inducible nitric oxide synthase |
| MAH | marketing authorization holder |
| MAOIs | monoamine oxidase inhibitors |
| MDD | major depressive disorder |
| NDRIs | noradrenaline and dopamine reuptake inhibitors |
| NE | noradrenaline (norepinephrine) |
| NF-κB | nuclear factor-kappa factor |
| NMDA | N-methyl-D-aspartate (glutamate receptors) |
| NRIs | noradrenaline reuptake inhibitors |
| OTC | over the counter (drugs) |
| OS | oxidative stress |
| SNRIs | selective noradrenaline reuptake inhibitors |
| SJW | St. John’s wort |
| TCAs | tricyclic antidepressants |
| TNF-α | tumour necrosis alpha |
| WHO | World Health Organization |